Tue, Mar 19, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Alternative Market Briefing

WBB enters buy-side with new healthcare long/short strategy

Tuesday, April 25, 2017

Benedicte Gravrand, Opalesque Geneva:

WBB Securities, a US financial services firm and boutique investment bank since 2001, has a long history within the biotech industry. Managing partner Steve Brozak has been associated with biotech for the last 25-30 years, and was involved with some of the most notable IPOs in the industry, such as Celgene. So launching a healthcare strategy out of their new asset management division (launched in September 16) was a logical step.

The strategy will focus on small caps (sub-$2 billion). Of the roughly 600 US-domiciled healthcare companies, about 80% are small-cap with little Street coverage.

"The investment opportunity set is mostly smaller, US-domiciled companies within the biotech industry, but also smaller pharmaceutical and medical device companies as well," managing director John Nolan told Opalesque. Nolan, who most recently served as vice president and co-head of quantitative investment research for manager selection at JPMorgan Chase, co-manages the fund with Brozak.

The strategy, which was launched on 3rd February, also applies a long/short and concentrated strategy, with about 20 positions.

It is concentrated because the managers want each position to individually have meaningful contribution to alpha. Funds that are too diversified, according to Nolan, start to resemble an index, "and just based on a tracking error, ......................

To view our full article Click here

Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1